Application of neoadjuvant therapy in the treatment of esophageal cancer

doi:10.3760/cma.j.cn371439-20190929-00011

Abstract

Abstract:

Neoadjuvant therapy combined with surgery is a very promising clinical treatment strategy for esophageal cancer. Combined with its effectiveness and safety, neoadjuvant radiotherapy can be used as a treatment method for severe esophageal cancer and unresectable esophageal cancer. Neoadjuvant chemotherapy has a higher value in the treatment of adenocarcinoma. Neoadjuvant cheoradiotherapy can be used as the recommended treatment scheme for patients with squamous cancer.

Key words: Esophageal neoplasms, Neoplasms,squamous cell, Adenocarcinoma, Neoadjuvant therapy

Bu Qian, Huang Junxing. Application of neoadjuvant therapy in the treatment of esophageal cancer[J]. Journal of International Oncology, 2020, 47(4): 244-248.

References 27

[1]	Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.v68.6
[2]	Chen W, Zheng R, Baade PD , et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.
[3]	汪楣, 谷铣之, 黄国俊 , 等. 食管癌术前放射治疗的前瞻性临床研究[J]. 中华放射肿瘤学杂志, 2001,10(3):168-171. DOI: 10.3760/j.issn:1004-4221.2001.03.007.
[4]	Thumallapally N, Meshref A, Mousa M , et al. Survival benefit of neoadjuvant versus adjuvant radiotherapy in lymph node positive esophageal cancer: a population based analysis[J]. J Gastrointest Oncol, 2017,8(5):825-832. DOI: 10.21037/jgo.2017.06.19.
[5]	Chan KKW, Saluja R, Delos Santos K , et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: a network meta-analysis[J]. Int J Cancer, 2018,143(2):430-437. DOI: 10.1002/ijc.31312.
[6]	谭黎杰, 汪灏, 唐汉 . 局部进展期食管癌新辅助治疗的现状与展望[J]. 中华消化外科杂志, 2017,16(5):450-453. DOI: 10.3760/cma.j.issn.1673-9752.2017.05.003.
[7]	闫海霞, 符国胜 . 术前放疗对食管癌患者影响的临床分析[J]. 当代医学, 2011,17(16):21-22. DOI: 10.3969/j.issn.1009-4393.2011.16.014.
[8]	Zhu Y, Liu M, Yun X , et al. Meta-analysis for the therapeutic effect of neoadjuvant therapy in resectable esophageal cancer[J]. Pathol Oncol Res, 2017,23(3):657-663. DOI: 10.1007/s12253-016-0164-4.
[9]	Hara H, Tahara M, Daiko H , et al. Phase Ⅱ feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma[J]. Cancer Sci, 2013,104(11):1455-1460. DOI: 10.1111/cas.12274.
[10]	Pasquali S, Yim G, Vohra RS , et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis[J]. Ann Surg, 2017,265(3):481-491. DOI: 10.1097/SLA.000000000000-1905.
[11]	Ma S, Yan T, Liu D , et al. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma[J]. Thoracic Cancer, 2018,9(2):310-315. DOI: 10.1111/1759-7714.12590.
[12]	Zheng Y, Li Y, Liu X , et al. Reevaluation of neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials over the past 20 years[J]. Medicine (Baltimore), 2015,94(27):e1102. DOI: 10.1097/MD.0000000000001102.
[13]	Tanaka K, Miyata H, Sugimura K , et al. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts[J]. Carcinogenesis, 2015,36(8):894-903. DOI: 10.1093/carcin/bgv067.
[14]	Yoshida N, Baba Y, Shigaki H , et al. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma[J]. Int J Clin Oncol, 2016,21(6):1071-1078. DOI: 10.1007/s10147-016-0994-9.
[15]	van Hagen P, Hulshof MC, van Lanschot JJ , et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. New Engl J Med, 2012,366(22):2074-2084. DOI: 10.1056/NEJMoa1112088.
[16]	Shapiro J, van Lanschot JJB, Hulshof MCCM , et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015,16(9):1090-1098. DOI: 10.1016/s1470-2045(15)00040-6.
[17]	Mantziari S, Gronnier C, Renaud F , et al. Survival benefit of neoadjuvant treatment in clinical T₃N₀M₀ esophageal cancer: results from a retrospective multicenter European study[J]. Ann Surg, 2017,266(5):805-813. DOI: 10.1097/SLA.000000000000-2402.
[18]	Yang H, Liu H, Chen Y , et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018,36(27):2097-2083. DOI: 10.1200/JCO.2018.79.1483.
[19]	刘施亮, 习勉, 杨雅迪 , 等. 局部晚期食管鳞癌新辅助放化疗联合手术治疗的临床疗效分析[J]. 中华放射肿瘤学杂志, 2015,24(3):232-236. DOI: 10.3760/cma.j.issn.1004-4221.2015.03.002. doi: 10.3760/cma.j.issn.1004-4221.2015.03.002
[20]	Hamai Y, Hihara J, Taomoto J , et al. Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer[J]. Dis Esophagus, 2015,28(4):358-364. DOI: 10.1111/dote.12207.
[21]	Ychou M, Boige V, Pignon JP , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol, 2011,29(13):1715-1721. DOI: 10.1200/JCO.2010.33.0597.
[22]	Ronellenfitsch U, Schwarzbach M, Hofheinz R , et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data[J]. Eur J Cancer, 2013,49(15):3149-3158. DOI: 10.1016/j.ejca.2013.05.029. doi: 10.1016/j.ejca.2013.05.029
[23]	Alderson D, Cunningham D, Nankivell M , et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2017,18(9):1249-1260. DOI: 10.1016/s1470-2045(17)30447-3.
[24]	Kumagai K, Rouvelas I, Tsai JA , et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis[J]. Eur J Surg Oncol, 2015,41(3):282-294. DOI: 10.1016/j.ejso.2014.11.039.
[25]	Stahl M, Walz MK, Riera-Knorrenschild J , et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial[J]. Eur J Cancer, 2017,81:183-190. DOI: 10.1016/j.ejca.2017.04.027. doi: 10.1016/j.ejca.2017.04.027
[26]	Deng HY, Wang WP, Wang YC , et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer[J]. Eur J Cardiothorac Surg, 2017,51(3):421-431. DOI: 10.1093/ejcts/ezw315.
[27]	Bibby BA, Reynolds JV, Maher SG . MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma[J]. PLoS One, 2015,10(7):e0134180. DOI: 10.1371/journal.pone.0134180.